Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. [electronic resource]
Producer: 20040618Description: 2184-91 p. digitalISSN:- 0732-183X
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bevacizumab
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Dose-Response Relationship, Drug
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Paclitaxel -- administration & dosage
- Proportional Hazards Models
- Survival Analysis
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.